HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged over 18%, with net profit attributable to shareholders for the first three quarters up more than 1.7 times year-on-year, and is expected to fully benefit from the transmission of AIDD wet-lab demand.

Biocytogen Pharmaceuticals-B (02315) surged over 18%, up 18.33% as of press time at HK$42.58, with turnover of HK$90.1765 million. On the news front, Biocytogen Pharmaceuticals recently released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of RMB1.403 billion, up 49.09% year-on-year; net profit attributable to shareholders of the listed company was RMB312 million, up 173.77% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB235 million, up 307.62% year-on-year. The announcement said the company's performance growth was mainly due to a substantial increase in revenue from its pharmacology and efficacy services and model animal business from the beginning of the year to the end of the reporting period. Guolian Minsheng Securities noted that Biocytogen Pharmaceuticals' new-generation AI-driven antibody discovery platform RenSuper builds a "sequence library + AI + automation" architecture, trained on more than 1 million fully human antibody sequences. AI completes structure prediction, epitope inference and functional ranking, while the automated system forms closed-loop iteration through high-throughput validation, which is expected to transform undruggable targets into scalable ADC and multispecific drug candidates. The brokerage believes that as demand for AIDD wet-lab experiments gradually transmits to the in vivo validation stage, Biocytogen Pharmaceuticals is expected to fully benefit.